Arrowhead Pharmaceuticals Inc. Common Stock (ARWR)

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNA…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

711

Website

arrowheadpharma.com/

Fundamentals

1-day range

$88.07$89.59

Market cap

$12.12B

P/E (trailing)

—

P/E (forward)

-18.20

EPS (trailing)

$-2.24

Dividend yield

—

Beta

1.27

Avg. volume

2.03M

Forecasts

11 analyst ratings

Arrowhead Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ARWR

  Arrowhead Pharmaceuticals Inc. Common Stock

  $84.91

  ▼ 4.15%
  Market cap $12.12BP/E —
  $21.06$95.49
• ELAN

  Elanco Animal Health Incorporated Common Stock

  $24.12

  ▼ 1.51%
  Market cap $12.85BP/E —
  $17.11$27.98
• MDGL

  Madrigal Pharmaceuticals Inc. Common Stock

  $534.12

  ▼ 1.76%
  Market cap $11.14BP/E —
  $393.61$615
• AXSM

  Axsome Therapeutics Inc. Common Stock

  $199.01

  ▼ 3.52%
  Market cap $10.86BP/E —
  $112.9$260.19
• ABVX

  Abivax SA American Depositary Shares

  $113.41

  ▼ 0.78%
  Market cap $10.74BP/E —
  $60.45$139
• SMMT

  Summit Therapeutics Inc. Common Stock

  $13.71

  ▼ 4.33%
  Market cap $10.41BP/E —
  $12.07$29.23
• CYTK

  Cytokinetics Incorporated Common Stock

  $72.17

  ▼ 7.36%
  Market cap $9.51BP/E —
  $35.22$88.31

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
  Yahoo · 8/17/2026
• Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome
  Benzinga · 8/17/2026
• ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
  Yahoo · 8/7/2026
• Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
  Yahoo · 8/6/2026
• HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120
  Benzinga · 8/6/2026
• ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG
  Yahoo · 8/5/2026
• Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...
  Yahoo · 8/5/2026
• Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
  Yahoo · 8/4/2026

• Hongbo Lu · May 12, 2026 · Sale

  3.0K @ $76.88
• James C. Hamilton · April 23, 2026 · Sale

  10.0K @ $75
• Daniel Joseph Apel · April 22, 2026 · Sale

  8.7K @ $71.92
• Daniel Joseph Apel · April 22, 2026 · Sale

  1.2K @ $70.45
• Daniel Joseph Apel · April 22, 2026 · Sale

  3.2K @ $70.11
• James C. Hamilton · March 5, 2026 · Sale

  10.0K @ $64.19

Institutional Ownership

March 31, 2026

Total shares held

114.19M

Total value held

$7.03B

Institutional holders

431